162 related articles for article (PubMed ID: 15781334)
41. In myelodysplastic syndromes progression to leukemia is directly related to PHA dependency for colony formation and independent of in vitro maturation capacity.
Schipperus MR; Hagemeijer A; Ploemacher RE; Lindemans J; Voerman JS; Abels J
Leukemia; 1988 Jul; 2(7):433-7. PubMed ID: 3393024
[TBL] [Abstract][Full Text] [Related]
42. Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells.
Akel SM; Atoum MF; Saleh SA; Awadallah SM
Saudi Med J; 2005 Oct; 26(10):1523-8. PubMed ID: 16228049
[TBL] [Abstract][Full Text] [Related]
43. [Apoptotic characteristics of CD34 positive cells in myelodysplastic syndromes].
Li X; Pu Q; Liu YZ; Tao Y; Ying SX; Jiang QY; Shi J
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):355-7. PubMed ID: 12941189
[TBL] [Abstract][Full Text] [Related]
44. Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities.
López-Holgado N; Arroyo JL; Pata C; Villarón E; Sánchez Guijo F; Martín A; Hernández Rivas JM; Orfao A; San Miguel JF; Del Cañizo Fernández-Roldán MC
Leuk Res; 2004 Nov; 28(11):1181-7. PubMed ID: 15380343
[TBL] [Abstract][Full Text] [Related]
45. [The effect of down regulating of p27 on the activity of hematopoietic progenitor cells derived from umbilical cord blood and bone marrow ex vivo].
Li L; Li XX; Cheng T
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):90-3. PubMed ID: 15921625
[TBL] [Abstract][Full Text] [Related]
46. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
[TBL] [Abstract][Full Text] [Related]
47. High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients determined by Papanicolaou-stained preparations.
Emura I
Lab Hematol; 2003; 9(1):42-6. PubMed ID: 12661827
[TBL] [Abstract][Full Text] [Related]
48. Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes.
Ogata K; Satoh C; Tachibana M; Hyodo H; Tamura H; Dan K; Kimura T; Sonoda Y; Tsuji T
Stem Cells; 2005 May; 23(5):619-30. PubMed ID: 15849169
[TBL] [Abstract][Full Text] [Related]
49. Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replication.
Costantini A; Giuliodoro S; Mancini S; Butini L; Regnery CM; Silvestri G; Greco F; Leoni P; Montroni M
AIDS; 2006 Aug; 20(13):1713-20. PubMed ID: 16931935
[TBL] [Abstract][Full Text] [Related]
50. A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells.
da Silva CL; Gonçalves R; Crapnell KB; Cabral JM; Zanjani ED; Almeida-Porada G
Exp Hematol; 2005 Jul; 33(7):828-35. PubMed ID: 15963859
[TBL] [Abstract][Full Text] [Related]
51. The clonogenic potential of selected CD34+ cells from patients with MDS appear preserved when tested ex vivo.
Davison GM; Novitzky N; Abdulla R
Leuk Res; 2011 Sep; 35(9):1200-4. PubMed ID: 21474180
[TBL] [Abstract][Full Text] [Related]
52. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
53. Human umbilical cord blood-derived stromal cell, a new resource of feeder layer to expand human umbilical cord blood CD34+ cells in vitro.
Gao L; Chen X; Zhang X; Liu Y; Kong P; Peng X; Liu L; Liu H; Zeng D
Blood Cells Mol Dis; 2006; 36(2):322-8. PubMed ID: 16500123
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
55. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
[TBL] [Abstract][Full Text] [Related]
56. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients.
Han Q; Sun Z; Liu L; Chen B; Cao Y; Li K; Zhao RC
Leuk Res; 2007 Nov; 31(11):1469-78. PubMed ID: 17360037
[TBL] [Abstract][Full Text] [Related]
57. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
58. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
59. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
60. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
